Success Stories
Sciformix Finds an eClinical Ally in Medrio
Medrio helped Sciformix reduce the cost and timeline of the study. Medrio’s fully cloud-based platform made sharing easier which allowed Sciformix to work independently and efficiently.
Medical Device Sponsor Deploys Medrio EDC and Yields a Multitude of Immediate Benefits
Perth, Australia-based Linear Clinical Research wanted to upgrade from capturing clinical trial data on paper at their Phase I site. They selected Medrio’s integrated Electronic Data Capture (EDC) and direct data capture (DDC) platform. This is the story of their vendor evaluation – and their success with Medrio.
Ancillarie Experiences Efficient Study Build with Medrio
It’s not often that two clinical data managers who are years apart in their experience feel equally at ease during a clinical trial. But this is precisely what took place at Ancillarie, a support services company that has been serving pharmaceutical and biotechnology companies since 2012.
Clindata Gains Efficiency for Animal Health with Medrio EDC
Clindata International, a South Africa-based CRO specializing in Animal Health clinical trials, has used Medrio EDC since 2013.
Swing Therapeutics Achieved 97% Patient Compliance with ePRO
Swing Therapeutics leveraged Medrio ePRO in a proof-of-concept for a decentralized hybrid study. Electronic Patient-Reported Outcomes (ePRO) technology was used to assess the results of varying digital therapies and the feasibility of conducting a largely virtual clinical study in a fibromyalgia population.
The Right EDC Gives Paragonix Technologies Ultimate Autonomy with a Lean Team
Paragonix Technologies selected Medrio EDC for their GUARDIAN-HEART clinical study. Electronic Data Capture (EDC) technology is being used to collect and manage registry data, examining the effect of controlled hypothermic preservation in heart transplantation.
TargetCancer Foundation Successfully Engages and Empowers Rare Cancer Patients with Medrio
TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is remotely enrolling a total of 400 patients in the United States using electronic informed consent.
Subscribe To Our Newsletter
